Equity Profile

ONC

BeOne Medicines AG

Health CareBiotechnology$31.5B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BeOne Medicines AG is a biotechnology company focused on developing innovative therapies for various diseases. As part of the health care sector, its advancements can significantly impact patient care and treatment options.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and growth potential, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales from its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ONC Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

83%

Avg EPS Surprise

+540.06%

Avg Stock Reaction

+0.16%

Last Quarter Recap

In Q1 2026, BeOne Medicines reported an impressive EPS of $3.24, significantly beating expectations. The stock reacted positively, gaining over 5% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's strong recent performance. However, there is uncertainty due to the lack of guidance.

Bull Case

If BeOne continues its trend of exceeding EPS expectations, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company fails to meet expectations or provide clear guidance, it may lead to a significant sell-off.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given the company's history of beating EPS estimates, this will be a critical indicator of its ongoing performance.

What insights can management provide regarding revenue growth and future guidance?

Clear guidance on revenue will help investors gauge the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate BeOne's ability to sustain its growth trajectory, given its recent strong EPS surprises.

Supporting Evidence

The company has consistently outperformed EPS estimates, suggesting strong operational execution.

Options pricing indicates a higher expected move than historical averages, signaling potential volatility.

The recent performance trend suggests that the company may have more momentum than analysts anticipate.

Key Risk

If EPS comes in below $2.50, it could undermine the bullish narrative and lead to a reevaluation of growth expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched due to the company's recent strong earnings surprises and the market's expectations for continued growth.

Bull Confirmed If

An EPS of $3.50 or higher would confirm the bullish case and indicate strong operational performance.

Bear Confirmed If

An EPS below $2.50 would confirm bearish sentiment and raise concerns about the company's growth.

Pre-Earnings Positioning

Options Market

Implied Move

±16.36%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±16.4% while ONC has averaged ±5.2% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.4%

Calls (2K)P/C Ratio: 0.50Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BeOne beats expectations, history suggests the stock could rise by around 5.3%, confirming the bullish outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await more clarity from management.

Miss

A miss could lead to a decline of approximately 7.5%, reflecting the market's disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on new product developments or pipeline updates.
2Insights into market demand for BeOne's therapies.
3Management's outlook on revenue growth for the next quarter.
4Details on any regulatory approvals or setbacks.
5Updates on partnerships or collaborations that could impact growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and growth potential, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales from its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ONC Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

83%

Avg EPS Surprise

+540.06%

Avg Stock Reaction

+0.16%

Last Quarter Recap

In Q1 2026, BeOne Medicines reported an impressive EPS of $3.24, significantly beating expectations. The stock reacted positively, gaining over 5% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's strong recent performance. However, there is uncertainty due to the lack of guidance.

Bull Case

If BeOne continues its trend of exceeding EPS expectations, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company fails to meet expectations or provide clear guidance, it may lead to a significant sell-off.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given the company's history of beating EPS estimates, this will be a critical indicator of its ongoing performance.

What insights can management provide regarding revenue growth and future guidance?

Clear guidance on revenue will help investors gauge the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate BeOne's ability to sustain its growth trajectory, given its recent strong EPS surprises.

Supporting Evidence

The company has consistently outperformed EPS estimates, suggesting strong operational execution.

Options pricing indicates a higher expected move than historical averages, signaling potential volatility.

The recent performance trend suggests that the company may have more momentum than analysts anticipate.

Key Risk

If EPS comes in below $2.50, it could undermine the bullish narrative and lead to a reevaluation of growth expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched due to the company's recent strong earnings surprises and the market's expectations for continued growth.

Bull Confirmed If

An EPS of $3.50 or higher would confirm the bullish case and indicate strong operational performance.

Bear Confirmed If

An EPS below $2.50 would confirm bearish sentiment and raise concerns about the company's growth.

Pre-Earnings Positioning

Options Market

Implied Move

±16.36%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±16.4% while ONC has averaged ±5.2% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.4%

Calls (2K)P/C Ratio: 0.50Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BeOne beats expectations, history suggests the stock could rise by around 5.3%, confirming the bullish outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await more clarity from management.

Miss

A miss could lead to a decline of approximately 7.5%, reflecting the market's disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on new product developments or pipeline updates.
2Insights into market demand for BeOne's therapies.
3Management's outlook on revenue growth for the next quarter.
4Details on any regulatory approvals or setbacks.
5Updates on partnerships or collaborations that could impact growth.